Matthew Herper on Muck Rack

Matthew Herper Verified

New York
Senior Editor — Forbes
As seen in:  Forbes

Forbes reporter covering science and medicine

The Top Drug Launches Of All Time

forbes.com — Expectations in the drug business have been getting extremely high. Hepatitis C drugs are generating some of the biggest annual sales ever. New medicines from Merck and Bristol-Myers Squibb that harness the immune system to fight tumors are generating huge excitement.

Regeneron's George Yancopoulos Becomes Pharma's First Billionaire R&D Chief

forbes.com — TWENTY-SEVEN YEARS AGO George Yancopoulos was a scientific superstar, a professor of biology at Columbia at age 28. But his father, a first-generation Greek immigrant, kept complaining about how little academia paid. So Yancopoulos, now 55, signed on with a nascent Tarrytown, N.Y.-based biotech firm called Regeneron-and has since led the invention of four approved drugs and a technology platform designed to invent more.
Jul 28, 2015

Regeneron's George Yancopoulos Becomes Pharma's First Billionaire R&D Chief $regn forbes.com/sites/matthewh…

Jul 28, 2015

RT @matthewherper: Regeneron's George Yancopoulos Becomes Pharma's First Billionaire R&D Chief $regn forbes.com/sites/matthewh…

Jul 28, 2015

RT @Forbes: George Yancopoulos is the first pharmaceutical research chief ever to become a billionaire: onforb.es/1IGpHPi pic.twitter.com/19v5olCRga

Jul 28, 2015

#Regeneron's $REGN George Yancopoulos Becomes Pharma's First #Billionaire R&D Chief onforb.es/1Kwjini via @forbes @matthewherper

Allergan: Pharma's Biggest Dealmaker Is On The Hunt Again

forbes.com — Allergan CEO Brent Saunders At age 45, Allergan Chief Executive Brent Saunders already pulled off something like $150 billion worth of deals. Now he's going to get ready to do it again. Last year alone Saunders was credited with an amazing $97 billion worth of mergers and acquisitions - sometimes as buyer, sometimes as [...]
Jul 27, 2015

Allergan: Pharma's Biggest Dealmaker Is On The Hunt Again onforb.es/1DJ34lQ $AGN $TEVA $MYL $BIIB

Full Interview: Allergan's CEO On Selling His Generics Business And What He'll Buy Next

forbes.com — In a period of just a few years, Allergan chief executive Brenton L. Saunders, 45, has become one of the biggest deal makers in the history of the pharmaceutical industry. As described in my February cover story, Saunders sold eye care giant Bausch & Lomb to Valeant Pharmaceuticals', then took over [...]
Jul 27, 2015

Full Interview: Allergan's CEO On Selling His Generics Business And What He'll Buy Next onforb.es/1VIRO3T $AGN $TEVA

Jul 27, 2015

So I just had a convo with @brentlsaunders about what today's deal means. I posted transcript. forbes.com/sites/matthewh…

Jul 27, 2015

RT @matthewherper: Full Interview: Allergan's CEO On Selling His Generics Business And What He'll Buy Next onforb.es/1VIRO3T $AGN $TEVA

Jul 27, 2015

RT @matthewherper: Full Interview: Allergan's CEO On Selling His Generics Business And What He'll Buy Next onforb.es/1VIRO3T $AGN $TEVA

Allergan To Buy Antidepressant Maker For $560 Million With Hopes Of Preventing Suicides

forbes.com — Brent Saunders, chief executive officer of Allergan Allergan,the drug giant that is famed for Botox but also makes antibiotics and an Alzheimer's treatment, will spend $560 million to purchase Naurex, an Evanston, Ill.-based developer of antidepressants that can work in hours, compared to weeks for existing depression pills.
Jul 26, 2015

$AGN to buy antidepressant maker for $560m in hopes of preventing suicides -- see @matthewherper story: forbes.com/sites/matthewh…

Jul 26, 2015

Here's @matthewherper on Actavis's new bout of deal-making since buying and becoming Allergan: forbes.com/sites/matthewh…

Jul 27, 2015

RT @Forbes: "Depression remains one of the largest unmet areas of medical need." onforb.es/1IpamjX

Allergan Buys Antidepressant Maker For $560 Million With Hopes Of Preventing Suicides

forbes.com — Brent Saunders, chief executive officer of Allergan Allergan,the drug giant that is famed Botox but also makes antibiotics and an Alzheimer's treatment, will spend $560 million to purchase Naurex, an Evanston, Ill.-based developer of antidepressants that can work in hours, compared to weeks for existing depression pills.
Jul 26, 2015

RT @matthewherper: Exclusive: Allergan To Buy Antidepressant Maker For $560 Million With Hopes Of Preventing Suicides onforb.es/1VGVmUu $ACT

Jul 26, 2015

Exclusive: Allergan To Buy Antidepressant Maker For $560 Million With Hopes Of Preventing Suicides onforb.es/1VGVmUu $ACT

The FDA Approves A Potent And Pricey Cholesterol-Lowering Shot

forbes.com — The Food and Drug Administration has approved Praluent, a new medicine to lower cholesterol in people who have established heart disease, for people whose risk of a heart attack or stroke is not being adequately controlled by existing drugs called statins. It might be a big step in the battle against [...]
Jul 24, 2015

The FDA Approves A Potent And Pricey Cholesterol-Lowering Shot onforb.es/1RYRDlI $REGN price: $40 per day. $SNY $AMGN

Jul 24, 2015

The FDA Approves A Potent And Pricey Cholesterol-Lowering Shot onforb.es/1RYRDlI via @forbes

The Anthem-Cigna Deal Raises A Big Question For The U.S. Insurance Business

forbes.com — Today's announcement that health insurer Anthem plans to spend $54 billion to buy its rival, Cigna, to create the largest health insurance country in America is a good time to talk about a hard reality: the U.S. health insurance industry hasn't done its job. This isn't really the companies' fault.
Jul 24, 2015

The Anthem-Cigna Deal Raises A Big Question For The U.S. Insurance Business onforb.es/1KogHf0

Jul 24, 2015

Anthem-Cigna deal raises a big question for the U.S. insurance business--and for you onforb.es/1KogHf0 @matthewherper via @forbes

Jul 24, 2015

More than 5 million OH lives to be under the Anthem-Cigna deal. Worth reading @matthewherper's industry critique: onforb.es/1JjlrUF

155 Angry Doctors Propose 7 Solutions For Terrifying Cancer Drug Prices

forbes.com — How furious do doctors and patients have to get about the exploding prices of cancer drugs before something happens to change our medical system? Probably even more angry than this: "A lot of people think this is a free market for these drugs and therefore there is an internal regulation but it isn't.
Jul 23, 2015

155 Angry Doctors Propose 7 Solutions For Terrifying Cancer Drug Prices onforb.es/1CXrJYK w/ response from $NVS CEO

Jul 23, 2015

I'm going to tweet my article on high cancer drug prices twice because I like it. onforb.es/1CXrJYK

Jul 23, 2015

RT @matthewherper: I'm going to tweet my article on high cancer drug prices twice because I like it. onforb.es/1CXrJYK

Jul 23, 2015

RT @matthewherper: I'm going to tweet my article on high cancer drug prices twice because I like it. onforb.es/1CXrJYK

Jul 23, 2015

Fear And Loathing In The Cancer Pharmacy onforb.es/1CXrJYK <--trying a different headline.

Show 5 more tweets from Matthew Herper, Dan Bigman and others...

Doctors Are Optimistic About Axovant's Experimental Alzheimer's Drug

forbes.com — Axovant, a drug company created by former hedge fund manager Vivek Ramaswamy, has become a battleground stock because some critics can't believe the company's experimental Alzheimer's drug, RVT-101, could possibly justify a $1.8 billion market capitalization when GlaxoSmithKline had previously deep-sixed the drug and sold it to Axovant for just [...]
Jul 22, 2015

Doctors Are Optimistic About Axovant's Experimental Alzheimer's Drug onforb.es/1CVkIaL $AXON

Jul 22, 2015

RT @matthewherper: Doctors Are Optimistic About Axovant's Experimental Alzheimer's Drug onforb.es/1CVkIaL $AXON

Jul 22, 2015

RT @matthewherper: Doctors Are Optimistic About Axovant's Experimental Alzheimer's Drug onforb.es/1CVkIaL $AXON

Jul 22, 2015

RT @matthewherper: Doctors Are Optimistic About Axovant's Experimental Alzheimer's Drug onforb.es/1CVkIaL $AXON

More Articles →
Jul 29, 2015

@walidgellad @hiltzikm does not sound wrong. I think there were other pre-approval costs but am on vacation.

Jul 28, 2015

RT @adamfeuerstein: $GILD Milligan on M&A: We're in terrific shape. We can be selective, take our time. Small deals or large, transformativ…

Jul 28, 2015

RT @ArmstrongDrew: So I guess the 2Q hepatitis C market didn't slow down. Gilead just blew away the street's 2Q estimates. Stock up: pic.twitter.com/UfyTEnd32j

Jul 28, 2015

$gild releases numbers and the entire biotech sector breathes a sigh of relief. Casey did not strike out.

Jul 28, 2015

RT @megtirrell: Big $GILD Q2 beat: adj EPS $3.15 vs $2.71 est rev $8.2B vs $7.61B est hep C WW $4.9B vs $4.31B est increase prod rev guid to $29B-$30B

Jul 28, 2015

RT @Dereklowe: An Irresponsible Statement About Curing Cancer: OK, let's stop doing this. Here's the head of the Fred Hutchin... bit.ly/1LTUFnL

Email Matthew by joining Muck Rack



Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.